Assessment of Nuclear Factor Kappa B Among Chronic Myeloid Leukemia Patients
Keywords:
Nuclear Factor Kappa b , Chronic Myeloid leukemia , Erythrocyte Sedimentation Rate.Abstract
Chronic myeloid leukemia (CML) model of disease characterized by Philadelphia chromosome as a result of the t(9;22) reciprocal translocation between chromosomes 9 and 22 and the translocation occur in hematopoietic stem cell The activation of Nuclear Factor Kappa B signaling has been observed to increase significantly in leukemic stem cells exposed to chemotherapy. The aim of study to investigate the level of Nuclear factor kappa b in patient that treated with chemotherapy and compare the concentrations of NF kb in two type of therapy. The research included 50 individuals from the Iraqi National Hematology Center/Al-Mustansiriyah
University and Baghdad Teaching Hospital diagnosed with Chronic Myeloid Leukemia, alongside 50 control participants matched for physical characteristics. The age range of the patients was between 20 and 70 years. The quantification of Nuclear Factor Kappa B concentration in plasma was determined through a quantitative sandwich enzyme immunoassay method ( ELISA).The number of total males with CML was low (23 out of 50 ; 46%) while the total females with CML was (27 out of 50; 54%). This study showed increased level of nuclear factor kappa b concentration in cml patients plasma that treated with glavic (2.105 ± 0.503) pg/ml compared with concentration of healthy group plasma (1.468 ±0.741) pg/ml. While the mean of Erythrocyte sedimentation rate in Cml patients was (23.0 ± 18.4 ) mm/hour while the mean of Erythrocyte sedimentation rate in healthy control was (6.04 ± 2.42) mm/hour. Our findings indicate that the levels of NK-KB exhibit a significant elevation in CML patients who treated with Glavic and Tasigna. Erythrocyte sedimentation rate in Cml patients was elevated.
Downloads
References
Bennett, J.H.( 1845) Case of Hypertrophy of the Spleen and Liver, which Death Took Place from Suppuration of the Blood. Edinb. Med. Surg. J., 413–423.
Melo JV.( 1997) BCR-ABL gene variants. Baillières Clin Haematol.;10:203–22.
Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer C, Bloomfield CD.( 1992) Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762) Blood.;80:2983–90.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
